Related Articles
Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma
Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland
Determination of EGFR and KRAS mutational status in Greek non‑small‑cell lung cancer patients
EGFR-tyrosine kinase inhibitor treatment in a patient with advanced non-small cell lung cancer and concurrent exon 19 and 21 EGFR mutations: A case report and review of the literature
Histological subtype and smoking status, but not gender, are associated with epidermal growth factor receptor mutations in non-small‑cell lung cancer